Semaglutide (Wegovy) vs Liraglutide (Saxenda)

The comparative efficacy of Wegovy and Saxenda has been established through their respective clinical trial programs and a direct head-to-head study.

The STEP 8 trial directly compared semaglutide 2.4 mg weekly to liraglutide 3.0 mg daily in 338 adults with obesity or overweight (without diabetes) over 68 weeks. This head-to-head comparison ^[3] demonstrated clear superiority for semaglutide. Mean body weight change was -15.8% with semaglutide versus -6.4% with liraglutide. The percentage of participants achieving 10% or more weight loss was 70.9% with semaglutide versus 25.6% with liraglutide. The percentage achieving 20% or more weight loss was 38.5% with semaglutide versus 6.0% with liraglutide.

In the broader STEP program, semaglutide 2.4 mg consistently produced approximately 14.9-16.0% body weight reduction across studies (STEP 1 and STEP 3). In the SCALE program for liraglutide, the SCALE Obesity and Prediabetes trial ^[5] showed 8.0% body weight reduction with liraglutide 3.0 mg versus 2.6% with placebo over 56 weeks.

For cardiovascular outcomes, Wegovy has demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in the SELECT trial ^[6] among overweight/obese adults with established cardiovascular disease. Saxenda does not have a completed cardiovascular outcomes trial for the weight management indication, though the LEADER trial for Victoza (liraglutide 1.8 mg, lower dose) showed cardiovascular benefits in type 2 diabetes patients.

The evidence clearly establishes semaglutide 2.4 mg (Wegovy) as the more effective GLP-1 agonist for weight loss, producing approximately 2.5 times the weight reduction of liraglutide 3.0 mg (Saxenda) in direct comparison.

Both Wegovy and Saxenda produce gastrointestinal side effects as their most common adverse events, consistent with the GLP-1 receptor agonist class.

In the STEP 8 head-to-head trial, gastrointestinal adverse events were reported by 84.1% of semaglutide-treated patients versus 82.7% of liraglutide-treated patients, showing similar overall rates. However, the specific pattern differed somewhat. Nausea was reported by 44% with semaglutide versus 39% with liraglutide. Diarrhea occurred in 30% versus 21%. Constipation in 24% versus 19%. Vomiting in 25% versus 16%. Treatment discontinuation due to adverse events was 3.2% with semaglutide versus 12.6% with liraglutide in STEP 8.

The higher discontinuation rate with liraglutide in STEP 8, despite similar or lower individual GI event rates, may reflect the daily injection burden and lower satisfaction with weight loss results, rather than worse tolerability per se.

Both medications carry the same boxed warning for thyroid C-cell tumors ^[1][2] based on rodent studies, and both are contraindicated in patients with medullary thyroid carcinoma or MEN 2 history. Shared warnings include pancreatitis ^[1][2], gallbladder disease, acute kidney injury, suicidal ideation, hypoglycemia (when used with insulin or sulfonylureas), and hypersensitivity reactions.

Saxenda has more extensive post-market safety data given its earlier approval (2014 vs. 2021), providing greater long-term safety experience. Both medications increase heart rate by 2-4 beats per minute on average.

Both Wegovy and Saxenda are expensive brand-name medications, though their pricing structures differ.

Wegovy has a list price of approximately $1,349 per month. Saxenda has a list price of approximately $1,350-$1,430 per month. Prices are roughly comparable at list level.

Insurance coverage for both medications is limited because they are classified as anti-obesity drugs. Many commercial insurance plans exclude weight management medications, and Medicare Part D has historically not covered them. Coverage is more likely if the prescription is for a specific comorbidity management program or if the employer has specifically included obesity pharmacotherapy in the benefit package.

Novo Nordisk manufactures both medications and offers savings programs for each. The Wegovy and Saxenda savings cards can reduce copays for eligible commercially insured patients. Patient assistance programs are available for qualifying uninsured patients.

Given that Wegovy produces approximately 2.5 times the weight loss of Saxenda at comparable cost, the cost-effectiveness analysis strongly favors Wegovy for patients who can access and tolerate it.

Wegovy and Saxenda differ significantly in their dosing schedules, which has a major impact on patient convenience and adherence.

Wegovy is administered as a once-weekly subcutaneous injection using a prefilled pen. The maintenance dose is 2.4 mg, reached through a gradual 16-20 week titration starting at 0.25 mg. This means 52 injections per year at maintenance.

Saxenda is administered as a once-daily subcutaneous injection using a prefilled pen. The maintenance dose is 3.0 mg, reached through a 4-5 week titration starting at 0.6 mg and increasing by 0.6 mg weekly. This means 365 injections per year at maintenance.

The convenience advantage of Wegovy's weekly dosing over Saxenda's daily dosing is substantial. Once-weekly injection is associated with better adherence in real-world studies of GLP-1 agonists. However, Wegovy's longer titration period (16-20 weeks vs. 4-5 weeks) means patients wait longer before reaching the full therapeutic dose.

Both require refrigeration before first use. Wegovy pens can be stored at room temperature for up to 28 days; Saxenda pens for up to 30 days.

Given the available clinical evidence, Wegovy is the preferred choice for most patients seeking GLP-1-based weight management therapy. The STEP 8 head-to-head trial clearly demonstrated that semaglutide 2.4 mg produces substantially more weight loss than liraglutide 3.0 mg (15.8% vs. 6.4%), and Wegovy's once-weekly dosing is more convenient than Saxenda's daily injection.

However, there are specific situations where Saxenda may be considered. If Wegovy is unavailable due to supply shortages, Saxenda provides an alternative GLP-1 option. If a patient does not tolerate semaglutide, liraglutide may be better tolerated by some individuals despite the same drug class. For adolescents aged 12-17 with obesity, Saxenda received FDA approval in 2020, though Wegovy was subsequently approved for adolescents ^[8][9] in 2022. If a patient prefers a faster dose escalation (4-5 weeks vs. 16-20 weeks to reach maintenance dose), Saxenda allows quicker titration.

Insurance coverage may also drive the decision. If a plan covers Saxenda but not Wegovy (or vice versa), access determines the practical choice.

Patients should not take both Wegovy and Saxenda simultaneously, as both are GLP-1 receptor agonists and combining them would increase the risk of severe side effects without proven additional benefit.

This information is for educational purposes only and does not constitute medical advice. Consult your healthcare provider to determine the most appropriate weight management treatment for your individual circumstances.